Next Generation HIV Vaccines and Therapies Web Banner

Web Desc
Next Generation HIV Vaccines & Therapies
Scientific Organizers: Michel C. Nussenzweig, Robert F. Siliciano, John R. Mascola and Margaret E. Ackerman
Date: March 27 - 30, 2022
Location: Fairmont Banff Springs, Banff, AB, Canada
Supported by the Directors' Fund
For important information on the coronavirus, please click here
Summary of Meeting:
Despite the many years of research, a successful vaccine or cure for HIV-1 remains among the highest priority areas of unmet need in infectious disease. As such, this Keystone Symposia conference was designed to bring together scientists working in the fields of HIV vaccines and/or the pathway to a cure. The program was designed to highlight recent results in both areas. The conference seeks to foster collaborations that will build upon these new results to help accelerate progress and treatment methods. The sessions in this program were developed to include a focus on novel approaches to vaccine development including vaccine immunology, passive therapies, and genetic vaccination. Additionally, results from ongoing human vaccine clinical trials will also be integrated into the conference. Moreover, sessions focused on a cure for HIV will address the problem of viral latency and how it is controlled and will emphasize cure-related human clinical trials. The conference organizers hope to elicit and identify areas of future investigation, encourage new partnerships, and collectively generate the knowledge required to design better vaccines, treatment methods, and networks that will facilitate transformative approaches to prevention and cure for this disease.
DEADLINES:
*All deadlines end at 11:59 PM US Mountain Standard Time
Scholarship Deadline: December 2 2021 details
Abstract Deadline: December 9 2021 details & pricing
Discounted Registration Deadline: January 26 2022 details & pricing


Keystone Symposia is committed to maintaining a positive and respectful environment at its meetings. To this end, please review and comply with our policies.


We gratefully acknowledge the generous grant for this conference provided by:

National Institute of Allergy and Infectious Diseases (NIAID)
Grant No. 1 R13 AI157805-01
Funding for this conference was made possible [in part] by 1 R13 AI157805 - 01 from the National Institute of Allergy and Infectious Diseases. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

No content found

No content found

No content found

No content found